摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-氯咪唑并[1,2-b]哒嗪-3-甲醛 | 154578-26-4

中文名称
6-氯咪唑并[1,2-b]哒嗪-3-甲醛
中文别名
6-氯咪唑并[1,2-B]哒嗪-3-甲醛
英文名称
6-chloroimidazo[1,2-b]pyridazine-3-carbaldehyde
英文别名
6-chloro-imidazo[1,2-b]pyridazine-3-carbaldehyde
6-氯咪唑并[1,2-b]哒嗪-3-甲醛化学式
CAS
154578-26-4
化学式
C7H4ClN3O
mdl
MFCD11044762
分子量
181.581
InChiKey
WYUDQEUQUMBLRF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.57±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.1
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    47.3
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2933990090
  • 危险性防范说明:
    P280,P305+P351+P338
  • 危险性描述:
    H302
  • 储存条件:
    2-8℃,在惰性气体氛围中进行。

SDS

SDS:60165cf81e0be79af50e17433fd860bc
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 6-Chloroimidazo[1,2-b]pyridazine-3-carbaldehyde
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloroimidazo[1,2-b]pyridazine-3-carbaldehyde
CAS number: 154578-26-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4ClN3O
Molecular weight: 181.6

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-氯咪唑并[1,2-b]哒嗪-3-甲醛 在 sodium tetrahydroborate 作用下, 以 甲醇 为溶剂, 反应 0.5h, 生成 6-氯-咪唑并[1,2-b]吡嗪-3-甲醇
    参考文献:
    名称:
    [EN] IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF
    [FR] COMPOSÉS À BASE D'IMIDAZO [1, 2-B] PYRIDAZINE, COMPOSITIONS LES COMPRENANT ET UTILISATIONS DE CEUX-CI
    摘要:
    基于咪唑并[1,2-b]吡啶嗪的化合物的公式(I)被披露,其中R1、R2和R3在此处被定义。还披露了包含这些化合物的组合物以及它们用于治疗、管理和/或预防由适配器相关激酶1活性介导的疾病和紊乱的方法。
    公开号:
    WO2013134219A1
  • 作为产物:
    描述:
    6-氯-咪唑并[1,2-b]吡嗪-3-甲醇二氧化锰 乙酸乙酯 作用下, 以 二氯甲烷 为溶剂, 反应 16.0h, 以to afford 6-chloro-imidazo[1,2-b]pyridazine-3-carbaldehyde (0.7 g) in 54% yield的产率得到6-氯咪唑并[1,2-b]哒嗪-3-甲醛
    参考文献:
    名称:
    Heterocyclic oxime compounds
    摘要:
    本发明涉及公式(I)的化合物及其盐:其中,取代基如规范中所定义;公式(I)的化合物用于治疗人体或动物体,特别是涉及c-Met酪氨酸激酶介导的疾病或病况;使用公式(I)的化合物制造治疗此类疾病的药物;包括公式(I)化合物的制药组合物,可选地与联合伙伴一起,以及制备公式(I)化合物的过程。
    公开号:
    US08410264B2
点击查看最新优质反应信息

文献信息

  • [EN] HETEROCYCLIC HYDRAZONE COMPOUNDS AND THEIR USES TO TREAT CANCER AND INFLAMMATION<br/>[FR] COMPOSÉS HYDRAZONE HÉTÉROCYCLIQUES ET LEURS UTILISATIONS POUR TRAITER LE CANCER ET L'INFLAMMATION
    申请人:NOVARTIS AG
    公开号:WO2011018454A1
    公开(公告)日:2011-02-17
    The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    该发明涉及公式(I)的化合物及其盐:其中取代基如规范中所定义;公式(I)的化合物用于治疗人体或动物体,特别是针对c-Met酪氨酸激酶介导的疾病或症状;公式(I)的化合物用于制造治疗此类疾病的药物;包含公式(I)的化合物的药物组合物,可选地与组合伙伴一起,并且公式(I)的化合物的制备方法。
  • [EN] HETEROCYCLIC OXIME COMPOUNDS<br/>[FR] COMPOSÉS D'OXIMES HÉTÉROCYCLIQUES
    申请人:NOVARTIS AG
    公开号:WO2011020861A1
    公开(公告)日:2011-02-24
    The invention relates to compounds of formula (I) and salts thereof wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    该发明涉及公式(I)的化合物及其盐,其中取代基如规范中所定义;公式(I)的化合物用于治疗人体或动物体,特别是针对c-Met酪氨酸激酶介导的疾病或症状;公式(I)的化合物用于制造治疗此类疾病的药物;包含公式(I)的化合物的药物组合物,可选地与组合伙伴一起,并且用于制备公式(I)的化合物的方法。
  • Dearomatization of Electron-Deficient Nitrogen Heterocycles via Cobalt-Catalyzed Asymmetric Cyclopropanation
    作者:Amruta Joshi-Pangu、Ryan D. Cohen、Matthew T. Tudge、Yonggang Chen
    DOI:10.1021/acs.joc.6b00322
    日期:2016.4.15
    The dearomatization of a series of electron-deficient nitrogen heterocycles has been achieved through a cobalt-catalyzed asymmetric cyclopropanation reaction. This reaction proceeds with high levels of enantio- and diastereoselectivity to afford unique cyclopropanes that can be further functionalized to provide complex heterocyclic building blocks.
    通过催化的不对称环丙烷化反应已实现了一系列电子不足的氮杂环的脱芳香化作用。该反应以高对映体和非对映体选择性进行,得到独特的环丙烷,其可以进一步官能化以提供复杂的杂环结构单元。
  • Efficient preparation of imidazo[1,2-b]pyridazines under Swern oxidative conditions
    作者:Pierre Raboisson、Belew Mekonnen、Norton P Peet
    DOI:10.1016/s0040-4039(03)00426-x
    日期:2003.3
    An efficient synthesis of new imidazo[1,2-b]pyridazine derivatives was effected by treating 3,6-dichloropyridazine with various 2-hydroxyethylamines following by imidazole ring formation under Swern oxidative conditions. Some mechanistic aspects of the cyclization step are discussed.
    通过在Swern氧化条件下形成咪唑环,用各种2-羟基乙胺处理3,6-二氯哒嗪,可以有效合成新的咪唑并[1,2- b ]哒嗪生物。讨论了环化步骤的一些机械方面。
  • HETEROCYCLIC OXIME COMPOUNDS
    申请人:DAI Miao
    公开号:US20110065708A1
    公开(公告)日:2011-03-17
    The invention relates to compounds of formula (I) and salts thereof: wherein the substituents are as defined in the specification; a compound of formula (I) for use in the treatment of the human or animal body, in particular with regard to c-Met tyrosine kinase mediated diseases or conditions; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharmaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner, and processes for the preparation of a compound of formula (I).
    本发明涉及公式(I)的化合物及其盐: 其中取代基如规范中所定义;公式(I)的化合物用于人或动物体内的治疗,特别是针对c-Met酪氨酸激酶介导的疾病或情况;使用公式(I)的化合物制造治疗此类疾病的药物;包括公式(I)的化合物的制药组合物,可选地与联合伙伴一起使用,以及制备公式(I)的化合物的过程。
查看更多